(firstQuint)Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine (GSK1437173A) in Adults  65 Years of Age With and Without Zostavax Vaccination at Least 5 Years Earlier.

 The study will evaluate two parallel groups of 200 adults 65 YOA; one group (Prev-Zvax) with a previous Zostavax(R) vaccination at least 5 years earlier, versus the other group without a previous Zostavax(R) vaccination (No prev-Zvax).

 The goal of this study is to generate immunogenicity, safety and reactogenicity data for the respective vaccines.

.

 Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine (GSK1437173A) in Adults  65 Years of Age With and Without Zostavax Vaccination at Least 5 Years Earlier@highlight

The purpose of this study is to evaluate the immunogenicity and safety of GSK Biologicals' HZ/su vaccine in adults 65 years of age with and without Zostavax(R) vaccination at least 5 years earlier.

